Zweegman S, Schjesvold FH, Van der Holt B, et al. Ixazomib-thalidomide-low dose dexamethasone (ITd) induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/Nmsg 21#13 Trial. ASH Annual Meeting and Exposition 2018, abstract 800.
Reactie op FREEDOM2-studie: “We moeten kritisch blijven, juist bij nieuwe middelen”
sep 2025 | MPN